Hikari Power’s Alexion Pharmaceuticals ALXN Stock Holding History

Hikari Power’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-5,000	Closed	-$608K	–	101
2017 Q2	$608K	Buy	+5,000	New	+$582K	0.08%	60

Other funds holding ALXN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Hikari Power's ALXN Position: Q3 2017 in Review

Hikari Power sold out of Alexion Pharmaceuticals (ALXN) in Q3 2017, closing a stake of 5,000 shares — an estimated $608K sold.

Hikari Power first reported a position in ALXN in Q2 2017 and held it in 1 quarter. The position peaked at $608K in Q2 2017. 595 funds tracked by Wall St. Rank hold ALXN as of Q3 2017.

Hikari Power reported no remaining Alexion Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
Hikari Power sold 5,000 Alexion Pharmaceuticals shares in Q3 2017, an estimated $608K.
Hikari Power first reported a position in Alexion Pharmaceuticals in Q2 2017 and held it in 1 quarter.
Hikari Power's Alexion Pharmaceuticals position peaked at $608K in Q2 2017.
595 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2017.

Based on Hikari Power's 13F filing for Q3 2017, filed 8 Nov 2017.